Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Singer BA, Arnold DL, Drulovic J, Freedman MS, Gold R, Gudesblatt M, Jasinska E, LaGanke CC, Naismith RT, Negroski D, Oh J, Hernandez Perez MA, Selmaj K, Then Bergh F, Wundes A, Ziemssen T, Castro-Borrero W, Chen H, Levin S, Scaramozza M, Shankar SL, Wang T, Wray S. Singer BA, et al. Among authors: levin s. Mult Scler. 2023 Dec;29(14):1795-1807. doi: 10.1177/13524585231205708. Epub 2023 Oct 31. Mult Scler. 2023. PMID: 37905526 Free PMC article.
Safety, tolerability, and efficacy of diroximel fumarate in a cohort of Black patients with multiple sclerosis from the phase 3 EVOLVE-MS-1 study.
Hunter SF, Lindsey JW, Osborne B, Schreiber B, Branco F, Levin S, Lewin JB, Scaramozza M, Tian Z, Antezana A. Hunter SF, et al. Among authors: levin s. Mult Scler Relat Disord. 2024 Nov;91:105912. doi: 10.1016/j.msard.2024.105912. Epub 2024 Sep 30. Mult Scler Relat Disord. 2024. PMID: 39393172 Free article. Clinical Trial.
Vaccine response in people with multiple sclerosis treated with fumarates.
Tremblay MA, Vukusic S, Shanmugasundaram M, Bozin I, Levin S, Gocke A, Wipfler P. Tremblay MA, et al. Among authors: levin s. Mult Scler J Exp Transl Clin. 2023 Sep 6;9(3):20552173231191170. doi: 10.1177/20552173231191170. eCollection 2023 Jul-Sep. Mult Scler J Exp Transl Clin. 2023. PMID: 37692293 Free PMC article. Review.
Manifestations and impact of the COVID-19 pandemic in neuroinflammatory diseases.
Levin SN, Venkatesh S, Nelson KE, Li Y, Aguerre I, Zhu W, Masown K, Rimmer KT, Diaconu CI, Onomichi KB, Leavitt VM, Levine LL, Strauss-Farber R, Vargas WS, Banwell B, Bar-Or A, Berger JR, Goodman AD, Longbrake EE, Oh J, Weinstock-Guttman B, Thakur KT, Edwards KR, Riley CS, Xia Z, De Jager PL; Multiple Sclerosis Resilience to COVID-19 (MSReCOV) Collaborative. Levin SN, et al. Ann Clin Transl Neurol. 2021 Apr;8(4):918-928. doi: 10.1002/acn3.51314. Epub 2021 Feb 22. Ann Clin Transl Neurol. 2021. PMID: 33616290 Free PMC article.
Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapses.
Epstein SE, Levin S, Onomichi K, Langston C, Yeshokumar A, Fabian M, Sand IK, Klineova S, Lublin F, Dykstra K, Xia Z, De Jager P, Levine L, Farber R, Riley C, Vargas WS. Epstein SE, et al. Among authors: levin s. Mult Scler Relat Disord. 2021 Nov;56:103229. doi: 10.1016/j.msard.2021.103229. Epub 2021 Aug 28. Mult Scler Relat Disord. 2021. PMID: 34479112 Free PMC article.
Fatal COVID-19 in an MS patient on natalizumab: A case report.
Rimmer K, Farber R, Thakur K, Braverman G, Podolsky D, Sutherland L, Migliore C, Ryu YK, Levin S, De Jager PL, Vargas W, Levine L, Riley CS. Rimmer K, et al. Among authors: levin s. Mult Scler J Exp Transl Clin. 2020 Aug 10;6(3):2055217320942931. doi: 10.1177/2055217320942931. eCollection 2020 Jul-Sep. Mult Scler J Exp Transl Clin. 2020. PMID: 32850133 Free PMC article.
2,191 results